Global dental duopoly (with Henry Schein/Patterson distribution and Envista brands) trading at 7.3x EV/EBITDA TTM vs peer median ~10x, with 12.3% short interest and a Return-to-Growth plan under new CEO Dan Scavilla. Stock sits $0.15 above 52W low ($8.38) despite reiterated FY26 guidance and $55M Q2 FCF. Thesis: EBITDA has stabilized, Wellspect grows +7% while legacy segments compress; a Q3 beat or any sign of Essential Dental stabilization triggers multiple expansion from 7x toward peer 9-10x.
Segmental EV/Sales SotP (primary) cross-checked with consolidated 8x EV/Adj EBITDA FY26E $700M. Implied multiple consistency verified at 7.5x. Sensitivity: ±1x on blended EV/EBITDA = ±$3.5/sh. Analyst consensus: ~$14.50 median; our $15.80 base is within +10% of consensus. Floor anchor: 6x × $550M Adj EBITDA bear case = $7.00 (bear). Asymmetry ratio = +85%/−18% = 4.7x. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Essential Dental Solutions (consumables) | $1,504M FY26E rev × 1.8x EV/Rev (vs HSIC/PDCO distribution ~0.5x; XRAY = branded consumables, closer to ALGN 2.9x; mid-point 1.8x reflects margin pressure) | +13.58 |
| Connected Technology Solutions (CAD/CAM equipment) | $956M FY26E rev × 0.8x EV/Rev (equipment cyclical, demand headwinds; vs Envista implants/equipment ~1.0-1.2x) | +3.84 |
| Orthodontic & Implant Solutions | $788M FY26E rev × 1.3x EV/Rev (declining −14% CC in Q2; vs ALGN 2.9x and EBS implants ~1.5x; discount for execution) | +5.14 |
| Wellspect Healthcare (continence care) | $344M FY26E rev × 3.0x EV/Rev (+7% organic, >25% EBITDA margin; comparable to Coloplast ~5x so prudent 3x applied) | +5.18 |
| Net debt | ($239M cash − $2,327M total debt) / 199.35M shares | −10.46 |
| Litigation reserve (pending class actions) | Mid-point of $50-150M expected settlement, risk-adjusted / 199.35M shares | −0.50 |
| FV base case | Sum of lines above: 13.58 + 3.84 + 5.14 + 5.18 − 10.46 − 0.50 | ≈ $16.78 |
Short interest at 12.3% signals persistent bearish positioning after multiple guidance resets 2022-2024. The elevated short + stable FCF + proximity to 52W low creates a classic reflexive setup: any positive data point (Q3 beat, guidance raise, M&A rumor) can trigger forced short covering. Historical pattern: dental-sector shorts have unwound violently (see Align 2023, Envista 2025 recoveries).
| Item | FY 2023 | FY 2024 | FY 2025 | TTM Jun'26 | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 3,965 | 3,793 | 3,680 | 3,643 | 3,500–3,600 |
| GAAP Operating Income ($M) | 289 | 222 | 245 | 177 | — |
| Adj EBITDA ($M) | ~820 | ~760 | ~700 | ~700 | ~700 |
| GAAP Net Income ($M) | −132 | −910 | −598 | −546 | — |
| Adj EPS ($) | 1.82 | 1.75 | 1.62 | 1.48 | 1.40–1.50 |
| Operating Cash Flow ($M) | 518 | 484 | 330 | 319 | — |
| Free Cash Flow ($M) | 265 | 265 | 95 | 143 | — |
| Total Debt ($M) | 2,318 | 2,289 | 2,479 | 2,327 | — |
| Cash ($M) | 367 | 302 | 354 | 239 | — |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 936 | 890 | 900 | 878 | 898 |
| CC organic growth % | −3.5% | −4.0% | −5.1% | −5.8% | −6.3% |
| Adj EBITDA ($M) | 197 | 175 | 168 | 160 | 190 |
| Adj EBITDA margin % | 21.0% | 19.7% | 18.7% | 18.2% | 21.3% |
| FCF ($M) | 16 | 42 | 50 | 40 | 55 |
| Cash EoP ($M) | 326 | 310 | 354 | 280 | 239 |
Business model — Dental incumbent + continence care
Essential Dental Solutions ~$1,500M FY26E (41% rev) 🟡 to be stabilized Dental consumables (prophy, endo, restoratives). Branded recurring revenue, >60% gross margins. Declining −5% CC due to channel destocking and lost shelf space. If this segment stops declining, the stock re-rates immediately. Connected Technology Solutions ~$950M FY26E (26% rev) 🟡 cyclical CEREC CAD/CAM chairside systems, Primescan intraoral scanners, imaging. Capital-equipment demand cyclical, hurt by dental practice capex softness. New CEREC MX released 2026 — needs to drive refresh cycle. Orthodontic & Implant Solutions ~$790M FY26E (22% rev) 🔴 stalled SureSmile aligners losing share vs Align/ClearChoice; Astra/Ankylos implants pressured by Straumann/Envista. Q2 CC: −14.9%. The weakest segment and the main source of thesis risk. Wellspect Healthcare ~$340M FY26E (12% rev) 🟢 growing +7% Continence care (catheters, LoFric brand), non-dental. >25% EBITDA margin, +7% organic Q2. Comparable to Coloplast business model. Potential spin-off/divestiture candidate — could unlock $800M-1B value alone.
Legal, regulatory and risk analysis
SWOT analysis
- +Global #2 dental consumables brand portfolio (Dentsply + Sirona heritage)
- +EBITDA margin stabilized at 20-21% through cost discipline
- +Positive FCF generation ($143M TTM) covers dividend + buyback + debt
- +Wellspect: hidden gem growing +7% with 25%+ EBITDA margin
- −6 consecutive quarters of negative organic growth
- −$2.1B net debt limits strategic flexibility (M&A, aggressive buyback)
- −Ortho/Implants losing share structurally to Align, Straumann
- −Governance history: multiple CEO changes, pending class actions
- →Wellspect spin-off/divestiture could unlock $1-1.7B embedded value
- →Multiple expansion from 7.3x to peer 9-10x adds $4-6/share mathematically
- →CEREC MX refresh cycle + end of channel destocking in 2027
- →PE / strategic takeover candidate at current valuation (EV/Sales 1.06x)
- !Continued share loss in Ortho/Implants (segment −15% CC)
- !Rate/credit tightening forces debt refinancing at worse terms
- !Class action settlement at upper range ($150M)
- !Dental practice capex cycle extends recession (CTS equipment)
Summary by assessment area
- Leverage 2.98x within covenants; positive FCF supports obligations
- Revenue decline is the main concern, not solvency
- Dividend safe at ~22% FCF payout; buyback modest ~$50M/yr
- FV base $15.80 implies +85% upside vs current $8.53
- 7.3x EV/EBITDA TTM vs peer median ~10x = ~45% discount
- Asymmetry ratio 4.7x: downside -18% to bear $7.00 anchor
- Nov 5 Q3 earnings is the catalyst: beat triggers re-rate, miss accelerates decline
- Ortho/Implants trajectory is the thesis-killer if it worsens
- Class action resolution timing uncertain, likely 12-24 months
Sources: Q2 2026 earnings release (Stocktitan, DENTSPLY SIRONA investor relations); stockanalysis.com statistics and financials (XRAY, Oct 12 2026 close); peer data from EBS, HSIC, PDCO, ALGN pages; Simply Wall St valuation summaries; class action notices (Kirby McInerney, Kessler Topaz, Howard G. Smith via Businesswire); Zacks and Barchart Q2 analysis. Market data — last verified close 2026-10-12: XRAY ~$8.53, market cap ~$1.70B, 52W: $8.38–$14.76, 199.35M shares outstanding. Short interest: 12.33%. Net debt: $2.09B. EV/EBITDA TTM: 7.3x. Next earnings: Nov 5, 2026 BMO. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.